The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Hydroxyamphetamine Hydrobromide / TropicamidePronunciation: hye-DROX-ee-am-FET-a-meen HYE-droe-BROE-mide/troe-PIK-a-mide
Class: Mydriatic combination
- Solution, ophthalmic hydroxyamphetamine hydrobromide 1%/tropicamide 0.25%
An indirect-acting sympathomimetic agent that causes the release of norepinephrine from adrenergic nerve terminals, resulting in mydriasis.Tropicamide
A parasympatholytic agent that produces mydriasis and paralysis by blocking the sphincter muscle in the iris and the ciliary muscle.
Indications and Usage
For mydriasis in routine diagnostic procedures and in conditions in which short-term pupil dilation is desired; provides clinically significant mydriasis with partial cycloplegia.
Hypersensitivity to hydroxyamphetamine, tropicamide, or any component of the formulation; angle-closure glaucoma or those with narrow angles in whom dilation of the pupil may precipitate an attack of angle-closure glaucoma.
Dosage and AdministrationAdults
Ophthalmic Instill 1 to 2 drops in the conjunctival sac(s).
- Do not allow tip of dropper bottle to touch eye, eyelid, fingers, or any other surface.
Store between 68° and 77°F. Protect from light.
None well documented.
Cardiorespiratory collapse; hypotensive episodes; MI; tachycardia; vasomotor collapse; ventricular fibrillation.
Behavioral disturbances; headache; psychotic reactions.
Blurred vision; increased IOP; photophobia with or without corneal staining; transient stinging.
Dryness of mouth; nausea; vomiting.
Allergic reactions; pallor.
Category C .
Safety and efficacy have not been established. Rarely, CNS disturbances, which may be dangerous in infants and children, may occur. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported.
Special Risk Patients
Patients with hypertension, hyperthyroidism, diabetes, or cardiac disease (eg, arrhythmias or chronic ischemic heart disease); elderly patients. Monitor patients with glaucoma or increased IOP closely following instillation.
To avoid inducing angle-closure glaucoma, make an estimation of the depth of the angle of the anterior chamber.
Cardiac arrhythmias, dilation of pupils, GI irritation, headache, hypertension, nausea, substernal discomfort, sweating, vomiting.
- Teach patient proper technique for instilling eye drops: Wash hands; do not allow tip of dropper bottle to touch eye, eyelid, fingers, or any other surface. Tilt head back, look up; pull lower eyelid down to form pocket; place prescribed number of drops in the pocket. Look downward before closing eye; apply pressure to lacrimal sac for 2 to 3 min. Do not rub eye. Wash hands (and child's hands) after instillation.
- Advise parent or guardian to discontinue therapy and notify health care provider immediately if any CNS disturbances, psychotic reactions, changes in thinking or behavior, or rapid heart rate occur.
- Warn patients that they may experience sensitivity to light, and to therefore protect their eyes in bright illumination while their pupils are dilated.
- Caution patients to avoid driving or engaging in hazardous activities while their pupils are dilated.
- Inform patients that blurred vision and sensitivity to light are the most common adverse reactions, and to contact their health care provider if these occur and are bothersome.
Copyright © 2009 Wolters Kluwer Health.